Seems like this latest announcement is just designed to advise a delay in the JORC reporting until Q4, couched in the usual positive terms but not saying much else.
No sudden rerate likely here imho, but all still positive for the patient ones.
EER Price at posting:
29.0¢ Sentiment: Buy Disclosure: Held